Pharmacokinetic/pharmacodynamic profile of voriconazole.
about
Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3ACandida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsVoriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipientsTherapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.Recurrent erythematous plaques on sun-exposed sites in an African American boy with chronic granulomatous diseaseIn vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3Voriconazole pharmacokinetics in liver transplant recipients.Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex DialyzersVoriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17Resolution of a fungal mycotic aneurysm after a contaminated steroid injection: a case reportPopulation pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphismEvaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infectionsPractice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Inflammation is associated with voriconazole trough concentrations.Steady-state plasma pharmacokinetics of oral voriconazole in obese adults.Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapyPharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.Antifungal wound penetration of amphotericin and voriconazole in combat-related injuries: case report.Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicityTrough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.In vitro study of the variable effects of proton pump inhibitors on voriconazoleTherapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patientsMulticenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review.Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Coccidioidomycosis in persons infected with HIV-1.Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy.Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation.Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.Combination Antifungal Therapy for Invasive Aspergillosis Revisited.Complexity of interactions between voriconazole and antiretroviral agents.Antifungal agents--clinical pharmacokinetics and drug interactions.Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation.
P2860
Q24317436-3947A4AF-60D4-4BA5-BD96-03C83A8D5FC4Q26863344-76AA402C-6E35-44A7-9E7F-1B0252BE76F7Q27012442-89EB5A3D-AF2B-4D72-AE8D-FAAB874A19D7Q30981299-EC71E73F-187E-46C5-97D6-ED38AF2BEC7AQ33555723-F67A15D9-3B9D-4DA0-8595-33F5A3C988DEQ33574651-BE2713E8-87D3-4021-BC98-415631A5BE99Q33613685-5EE7A04C-54F2-4623-84EF-A7115C0F76A1Q33681401-84EF447D-D625-4C5F-8C19-C3F92735DB9EQ33684379-84F0AE97-78F7-4DC7-9235-8D151E66FB48Q33692784-BB81D2FA-637C-43BA-A3E4-86A5A22EC5BCQ33756583-769842D3-93CC-406B-986E-F4FB9BD90310Q34058346-26ECAB8E-9537-405A-B22C-3D3196A829DBQ34138276-6450D0F5-5000-47CB-AEE9-6770DBB0F673Q34150943-2FD116B0-2464-4BA9-A2A6-6BA7068F1AA2Q34213621-20402009-3A76-4E1F-A6B5-80F94B5B7D38Q34483712-E8C7BA98-DA32-4142-BE7C-D04DBF4CA8F7Q34532546-5F179270-8C23-479F-992B-3F6AEE1E1407Q34597394-1006E533-5B69-4883-8D96-00538B24087AQ35004898-C17878ED-2D0C-489A-9C40-598C64375896Q35114591-6E4FEAC5-D427-4BEA-9E78-1B64F192EED9Q35364006-1B48154E-EA82-47D1-977A-218AB2510CBAQ35493738-C9910275-AB23-49C2-A3FC-22F315C76FDCQ35672258-7F042F50-D70E-4E38-913F-C88D6D447F37Q35941502-22F568E0-2AC7-4CDE-A945-78E9A9D6E814Q35954530-B82731C4-EE7F-4F7D-BD0F-DFDECA9FC55CQ35960842-2AF7B606-6EAE-41BB-816D-E4BEF2238B56Q35973543-37A088C0-0DBE-4D37-BB49-B23E47302CFDQ36087577-2F3BF066-B6E8-42D2-B519-34664D9472E4Q36172497-215B5063-ECBB-488E-95C4-23DC705085FBQ36273788-564A1F21-3AD0-4836-86F6-833C5B00463CQ36608562-C332E2F1-AB80-446D-BDB0-C1D77CF3E141Q36760910-75DDAD1F-AE12-4F2C-B1A9-7F0BBD5A4E7BQ36867435-8FAAAE01-E530-4F63-A7CE-C294696E3391Q36887922-F23295E8-C7DC-468A-82D7-064530D9CA1BQ36969849-EB29F203-A3B3-4D02-B8D3-0DC87A3A7716Q37072046-192BDEA5-50E6-40E2-AA33-E733D11E1E67Q37103519-5CC5361A-D34A-4660-B5D3-F1CD0EC9857BQ37138857-85C317A3-26D4-4B60-9D12-109E6C8336A1Q37159568-FC2805A8-01DA-4877-A73B-E0EACFEAFFA9Q37190736-D72E7DCF-91FC-47D1-8724-82C11ECECCCD
P2860
Pharmacokinetic/pharmacodynamic profile of voriconazole.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Pharmacokinetic/pharmacodynamic profile of voriconazole.
@ast
Pharmacokinetic/pharmacodynamic profile of voriconazole.
@en
type
label
Pharmacokinetic/pharmacodynamic profile of voriconazole.
@ast
Pharmacokinetic/pharmacodynamic profile of voriconazole.
@en
prefLabel
Pharmacokinetic/pharmacodynamic profile of voriconazole.
@ast
Pharmacokinetic/pharmacodynamic profile of voriconazole.
@en
P2093
P2860
P1476
Pharmacokinetic/pharmacodynamic profile of voriconazole.
@en
P2093
Franziska Ihle
Hartmut Derendorf
Ursula Theuretzbacher
P2860
P304
P356
10.2165/00003088-200645070-00002
P577
2006-01-01T00:00:00Z
P5875
P6179
1037510163